ClinicalTrials.gg
CompletedNCT02911402SICKVESTUpdated Feb 15, 2022

Motion Sickness on Astrolabe's Vessel

An observational study in Sea Sickness, sponsored by University Hospital, Caen. Completed at 1 site in France. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-15.

Sponsored by University Hospital, Caen · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
147
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Sea sickness syndrome is present for 80% of persons on board when the boat rotation missions Astrolabe, sometimes there is a risk of very significant dehydration. A special unit specialized in the fundamental study of the vestibular system (inner ear), sensory organ at the base of visual-vestibular conflict inducing this syndrome, also provides medical support for parabolic flights (flight reproducing weightlessness) where this syndrome is strongly present. The goal of the study is to assess the frequency of occurrence of this sea sickness syndrome on the Astrolabe, to understand the triggers (type of boat movements, personality traits, anxiety / stress) without changing habits on board for those on board taking a antinaupathique treatment given by the ship's doctor. This study will be done in collaboration between INSERM U 1075 (France) and the Laboratory of military research VIPER specialized in extreme environments (Belgium). The ultimate goal will be to provide the best recommendations and the best treatment regimen to alleviate as best as possible the symptoms of people on board of the Astrolabe so scientists on board can perform their work.

Read the detailed description

Background: The objectives were to assess the prevalence, severity, medication taken and to look for predictive factors, in order to better identify characteristics of passengers at risk of motion sickness during transport scientists travelling from Hobart in Tasmania to the French polar stations in Antarctica.

Methods: Two hundred and thirty-nine passengers were surveyed over 4 years with 4 round trips per year using Motion Sickness Susceptibility Questionnaire (MSSQ), Simulator Sickness Questionnaire (SSQ), state-trait anxiety test (STAI-Trait and STAI-State), and general parameters (age, gender, number of trips, jet-lag, direction of the trip), medication, calculation of the distance of each passenger's cabin to the Centre of Gravity (CoG.).

02

Conditions studied

  • Sea Sickness

Browse trials for

03

In context

Motion Sickness

50 studies on the registry are indexed under Motion Sickness; 9 are open to participants now.

Browse Motion Sickness studies →

Lead sponsor

University Hospital, Caen is the lead sponsor of 512 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Astrolabe passengers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participant aged of 18 or older but younger than 70 who received their medical ability to travel to Terre Adélie or making a research cruise aboard the Astrolabe
  • particpant signing the .

Exclusion criteria

Exclusion Criteria:

  • none
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
147 participants (actual)
Patient registry
No

Interventions

  • Othersea sickness questionnaires
06

What researchers measure

Primary outcomes

  1. Motion Sickness susceptibilty questionnaire (fMSSQ)

    Sensitivity of motion sickness

    Time frame: day 1 to day 10

  2. STAY-YA questionnaire

    anxiety

    Time frame: day 1 to day 10

  3. STAY-YB questionnaire

    anxiety

    Time frame: day 1 to day 10

  4. Vis-Morgen Questonnaire about sleeping

    Subjective sleep scoring

    Time frame: day 1 to day 10

  5. Fatigue questionnaire

    Tiredness

    Time frame: day 1 to day 10

  6. Dietary intake survey

    food intake

    Time frame: day 1 to day 10

Secondary outcomes

  1. type of movement from the ship using use the data from the Dynamic Positioning System on board

    boat motion

    Time frame: baseline and every day up to 10 days

  2. data from individual actigraphs worn by the participants

    this will allow to quantify particpant's movements related to the ship movement

    Time frame: baseline and every day up to 10 days

  3. personnality questionnaire (OCEAN)

    Personnality

    Time frame: baseline and every day up to 10 days

  4. anxiety questionnaire (STAY).

    anxiety

    Time frame: baseline and every day up to 10 days

  5. treatment taken (international denomination and dose)

    treatment taken by subject for motion sickness

    Time frame: baseline and every day up to 6 days

07

Study locations

1 site
  • Caen University Hospital
    Caen, 14033, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02911402
Responsible party
Sponsor
First posted
Sep 22, 2016
Start date
Oct 2014
Primary completion
Dec 2017
Completion
Dec 2018
Last update
Feb 15, 2022

Study contacts

stephane Besnard, MD
principal investigator · CaenHU

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion